Abstract

The recent advances in in vitro 3D culture technologies, such as organoids, have opened new avenues for the development of novel, more physiological human cancer models. Such preclinical models are essential for more efficient translation of basic cancer research into novel treatment regimens for patients with cancer. Wild-type organoids can be grown from embryonic and adult stem cells and display self-organizing capacities, phenocopying essential aspects of the organs they are derived from. Genetic modification of organoids allows disease modelling in a setting that approaches the physiological environment. Additionally, organoids can be grown with high efficiency from patient-derived healthy and tumour tissues, potentially enabling patient-specific drug testing and the development of individualized treatment regimens. In this Review, we evaluate tumour organoid protocols and how they can be utilized as an alternative model for cancer research.

Keywords

OrganoidCancerEmbryonic stem cellComputational biologyTranslational researchBiologyDrug discoveryDrug developmentCancer treatmentMedicineBioinformaticsCancer researchNeurosciencePathologyDrugInternal medicinePharmacologyGeneGenetics

MeSH Terms

Adult Stem CellsBiomedical ResearchGene EditingHumansModelsBiologicalNeoplasmsOrganoidsPhenotypeTissue Culture TechniquesTranslational ResearchBiomedical

Affiliated Institutions

Related Publications

Publication Info

Year
2018
Type
review
Volume
18
Issue
7
Pages
407-418
Citations
1577
Access
Closed

Social Impact

Altmetric

Social media, news, blog, policy document mentions

Citation Metrics

1577
OpenAlex
37
Influential

Cite This

Jarno Drost, Hans Clevers (2018). Organoids in cancer research. Nature reviews. Cancer , 18 (7) , 407-418. https://doi.org/10.1038/s41568-018-0007-6

Identifiers

DOI
10.1038/s41568-018-0007-6
PMID
29692415

Data Quality

Data completeness: 86%